With all the breaking news on vaccines and variants I’ve barely had a chance to talk about this piece on microbes moving between humans and animals.
I think it’s important for the conversations we’re having around #sarscov2.
So, piece is here: sciencemag.org/news/2021/01/w…
And a thread
I’ve long been interested in the way infectious diseases affect wild animals and what we can learn about human disease from this.
So in 2019 I joined @Leendertz_Lab on a research trip to Taï National Forest in Cote d’Ivoire, where he has been studying this for 20 years.
@Leendertz_Lab The research station in Taï goes back to Christophe Boesch and Hedwige Boesch-Achermann who came to the forest in 1979 to study the chimpanzees. It took them years to habituate the animals (get them used to humans). Ever since then, researchers have been following them.
@Leendertz_Lab In 1994, chimpanzees started dying. The researchers dissected one of the chimps on the dining table of their camp (they wore gloves, but no gowns or masks). A week later, a woman from the team fell ill (she recovered). It turned out to be a new species of Ebola: Taï forest Ebola.
@Leendertz_Lab It was a wake-up call, Boesch says today. Infectious diseases were clearly more important than zoology had taught him.
And he decided to get a vet to permanently track the animals’ health and study their infections. Fabian Leendertz took that job 20 years ago.
@Leendertz_Lab Leendertz and his colleagues have studied many pathogens and outbreaks. On the trip in 2019 he was actually looking to see Woodstock, a chimp that had recently been diagnosed with leprosy, a disease never described in wild chimps before.
(My story here: sciencemag.org/news/2020/11/l…).
@Leendertz_Lab Long story (for another time), but Leendertz and I never got to see Woodstock on that trip. We hiked through the forest at night to where he had made his nest, but apparently he had left it before sunrise.
Here’s a photo of Leendertz listening for any noise that morning:
@Leendertz_Lab One of the saddest, most important findings of Leendertz' career was a paper published in 2008 showing that the researchers in Taï had themselves caused several outbreaks with human respiratory pathogens that had killed many chimpanzees. sciencedirect.com/science/articl…
@Leendertz_Lab “Reverse zoonoses” is what @GoldbergTony calls this.
He told me: “It’s a world of viruses that are crossing species in every direction and whenever that happens, it can cause devastating losses.”
Indeed there is a lot of that happening as Goldberg, Leendertz and others show.
@Leendertz_Lab@GoldbergTony 1. Diseases like #sarscov2 don’t strike us like lightning out of a blue sky. There is thunder and lightning all around us all the time.
But we only sit up and notice on the rare occasions when lightning strikes a human. Actually, sadly, a human from a rich western country.
So I think of researchers like Leendertz, Goldberg, @EpsteinJon and others as the people who do not just investigate lightning strikes. They investigate the thunder too, the storm clouds gathering, the electricity building up, the lightning that we missed - and that missed us.
@EpsteinJon 2. Infectious diseases are not on a one-way street from animals to humans. With our encroachment on nature, we are not just putting ourselves at risk but also animals that are already threatened by extinction.
We need to talk about this aspect of the animal-human interface too!
@EpsteinJon As @KJHockings told me about the chimpanzees: “On top of all of the deforestation, the poaching … they are just getting bashed by these infectious diseases.”
So a threat like #sarscov2 has to be taken seriously as a potential threat to these animals too, not just to humans.
„The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency. But the outcome reported here is clear and the scientific principle of vaccination is demonstrated ...“ thelancet.com/journals/lance…
Authors end that comment in Lancet by pointing that the result „means another vaccine can now join the fight to reduce the incidence of #COVID19“.
First results (yes, really!) on what #b117 + E484K might mean from @GuptaR_lab:
„Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralizing activity by vaccine-elicited antibodies“
Quick explainer:
The researchers took blood from 23 people vaccinated with Pfizer vaccine and then checked how well it neutralized retroviruses that they had engineered to contain the spike protein of #b117 with or without E484K.
Preprint is here: citiid.cam.ac.uk/wp-content/upl…
Interpretation:
This is roughly what I expected given B.1.351 and P.1 data.
If you‘ve followed my reporting the last weeks you know that it is difficult to know whether/how much a drop in neutralization in the lab will translate into a drop in vaccine efficacy in the real world.
And now for the bad news. *sigh*
It looks like #B117, the more transmissible variant first detected in England, has now picked up the E484K mutation as well. That is the one linked to evading SOME immunity in SAfrica and Brazil.
@_b_meyer "Preliminary information suggests more than one acquisition event.”
If this is true, it is one more sign that this mutation is a relatively easy way for the virus to acquire some advantage in populations with some immunity.
I worry that we will see this in many places with B117.
@_b_meyer And as @_b_meyer points out it may very well be that a mutation like N501Y makes it more likely for the virus to acquire this mutation because it almost “needs" it.
(Or as @K_G_Andersen would probably say: Maybe Nelly kinda seeks out the bad guys… )
More vaccine news, this time from phase 3 trial of Johnson&Johnson:
According to the company, their vaccine based on an adenovirus was 66% effective at preventing moderate and severe #covid19, 28 days after vaccination.
Good news:
- Big study with 45,000 participants across multiple countries
-Vaccine was 85% effective in preventing severe disease overall
- all hospitalisations and deaths in placebo group
- efficacy against severe disease increased over time (no cases in vaccinees after day 49)
Most importantly:
This is a single-dose vaccine and only needs standard refrigeration.
That means of vaccines so far it is the easiest to distribute.
And plan is to produce one billion doses this year, so protection for one billion people hopefully.
Just listened to a fascinating webinar by @ShabirMadh presenting the results from Novavax trial in South Africa and UK.
So will turn this into a brief thread to give some context on what we know so far and what the trial results (probably) mean:
First of all, this vaccine uses a more traditional approach than the mRNA vaccines we have been talking about a lot: It essentially consists of particles studded with the crucial spike protein plus an adjuvant to induce a potent immune response.
The study: This was a phase 2 study with just over 4400 participants and initially designed to look at HIV- people only. @ShabirMadh says they had “ to really work hard to get Novavax and everyone else to agree to do a sample of HIV-infected individuals”, which is crucial in SA.
“The world is at a critical juncture. With the emergence of new, more transmissible variants globally ... every country is now at risk of returning to square one unless we redouble our efforts to supress #Covid19 everywhere”, says @JeremyFarrar in new statement.
@JeremyFarrar “Vaccine nationalism doesn’t serve anyone. At the moment, vaccines are in short supply. But the new variants are an urgent warning of what is coming… .
It is in the national interest of all countries to bring infections down globally as much as possible."
@JeremyFarrar “Vaccinating a lot of people in a few countries, leaving the virus unchecked in large parts of the world, will lead to more variants .... The more that arise, the higher the risk of the virus evolving to an extent where our vaccines, treatments and tests are no longer effective."